Influence of Xiaoshuan enteric-coated capsules + aniracetam therapy on cerebral blood perfusion and nerve function in patients with convalescent cerebral infarction

Objective: To investigate the influence of Xiaoshuan enteric-coated capsules + aniracetam therapy on cerebral blood perfusion and nerve function in patients with convalescent cerebral infarction. Methods: A total of 177 cases of patients with convalescent cerebral infarction were retrospectively reviewed and then divided into the control group (n=109) and the Xiaoshuan enteric-coated capsules group (n=68). Control group received aniracetam therapy on the basis of routine treatment, and Xiaoshuan enteric-coated capsules group received Xiaoshuan enteric-coated capsules + aniracetam therapy on the basis of routine treatment. The differences in ultrasound cerebral blood perfusion parameter levels as well as serum neurotrophy index and nerve injury index contents were compared between the two groups. Results: Before treatment, there was no statistically significant difference in ultrasound cerebral blood perfusion parameter levels as well as serum neurotrophy index and nerve injury index contents between the two groups. After treatment, ultrasound cerebral blood perfusion parameters PSV and TMV levels in Xiaoshuan enteric-coated capsules group were higher than those in control group whereas RI level was lower than that in control group;serum neurotrophy indexes bFGF, BDNF and VEGF contents were higher than those of control group;serum nerve injury indexes GFAP, NSE, UCH-L1 and S100B contents were lower than those of control group. Conclusion: Xiaoshuan enteric-coated capsules + aniracetam therapy can significantly increase cerebral blood perfusion and optimize nerve function in patients with convalescent cerebral infarction.

Effect of oral erythromycin on gastric and small bowel transit time of capsule endoscopy

AIM: To determine the effect of oral erythromycin on gastric and small bowel transit time of capsule endoscopy.METHODS: Consecutive patients who underwent capsule endoscopy du ring the 16-mo study period were either given 250 mg oral erythromycin, 1 h prior to swallowing the capsule endoscope or nothing. The gastric and small bowel transit time, and the small bowel image quality were compared.RESULTS: Twenty-four patients received oral erythromycin whereas 14 patients were not given any prokinetic agent.Patients who received erythromycin had a significantly lower gastric transit time than control (16 min vs70 min, P= 0.005),whereas the small bowel transit time was comparable between the two groups (227 min vs183 min, P = 0.18).Incomplete small bowel examination was found in three patients of the control group and in one patient of the erythromycin group. There was no significant difference in the overall quality of small bowel images between the two groups. A marked reduction in gastric transit time was noted in two patients who had repeat capsule endoscopy after oral erythromycin.CONCLUSION: Use of oral erythromycin significantly reduces the gastric transit time of capsule endoscopy.

Effect of erythromycin on image quality and transit time of capsule endoscopy: A two-center study

AIM: To compare the effect of oral erythromycin vs no preparation with prokinetics on the transit time and the image quality of capsule endoscopy (CE) in evaluating small bowel (SB) pathology. METHODS: We conducted a retrospective, blinded (to the type of preparation) review of 100 CE studies, 50 with no preparation with prokinetics from one medical center (Group A) and 50 from another center with administration of a single dose of 200 mg oral erythromycin 1 h prior to CE (Group B). Gastric, SB and total transit times were calculated, the presence of bile in the duodenum was scored, as was cleanliness within the proximal, middle and distal intestine. RESULTS: The erythromycin group had a slightly shorter gastric transit time (21 min vs 28 min, with no statistical significance). SB transit time was similar for both groups (all P > 0.05). Total transit time was almost identical in both groups. The rate of incomplete examination was 16% for Group A and 10% for Group B (P = 0.37). Bile and cleanliness scores in different parts of the intestine were similar for the two groups (P > 0.05). CONCLUSION: Preparation for capsule endoscopy with erythromycin does not affect SB or total transit time. It tends to reduce gastric transit time, but it does not increase the cecum-reaching rate. Erythromycin does not adversely affect image quality. We consider the routine use of oral erythromycin preparation as being unjustified, although it might be considered in patients with known prolonged gastric emptying time.

Capsule endoscopy: Improving transit time and image view

AIM: To evaluate the effect of various methods of small bowel preparation on the transit time and the quality of visualization of the entire small bowel mucosa.METHODS: Ninety-five patients underwent capsule endoscopy (CE) by easily swallowing the capsule. They were divided into three study groups according to the preparation used: group A (n = 26) by polyethylene glycol (PEG) liter or with sodium phosphate (SP) 12 h prior to the CE study; group B (n = 29) by erythromycin 1 h prior to the CE study; and group C (n = 40) without any preparation. Visualization ranged from good to satisfactory to poor.RESULTS: The gastric emptying time in the group prepared with erythromycin was shorter but without statistical significance and the small bowel transit time was unaffected. In elderly subjects prepared by PEG or SP, the gastric emptying time was significantly longer (163.7 min, P = 0.05). The transit times of the three sub-groups were not affected by gender or pathology.The grade of cleaning of the entire study group was 3.27±1.1. The erythromycin group presented significantly the worst quality of images (P = 0.05) compared to the other sub-groups. Age, gender, and pathology had no effect on the quality of the cleaning of the small bowel in the sub-groups. One (1.05%) case had no natural excretion.CONCLUSION: Erythromycin markedly reduces gastric emptying time, but has a negative effect on the quality of the image in the small bowel. The preparation of elderly subjects with PEG or SP has a negative effect on the small bowel transit time.

阿奇霉素肠溶胶囊与红霉素肠溶胶囊用于咳嗽变异性哮喘合并肺炎支原体感染患儿的疗效及安全性比较

目的:比较阿奇霉素肠溶胶囊与红霉素肠溶胶囊用于咳嗽变异性哮喘合并肺炎支原体(mycoplasma pneumoniae,MP)感染患儿的疗效及安全性。方法:选取2016年11月至2018年10月东莞市人民医院收治的咳嗽变异性哮喘合并MP感染患儿110例,根据诊治时间进行排序,奇数为观察组,偶数为对照组,每组55例。对照组患儿给予常规治疗+红霉素肠溶胶囊治疗,观察组患儿给予常规治疗+阿奇霉素肠溶胶囊治疗。观察两组患儿的症状改善情况、炎性因子水平、临床疗效和不良反应发生情况。结果:治疗后,观察组患儿的症状评分、睡眠质量评分明显优于对照组,差异均有统计学意义(P<0.05);观察组患儿IL-2、IL-4及IL-10水平明显优于对照组,差异均有统计学意义(P<0.05);观察组患儿的总有效率为89.1%(49/55),明显高于对照组的70.9%(39/55),差异有统计学意义(P<0.05)。观察组、对照组患儿的不良反应发生率分别为16.4%(9/55)、18.2%(10/55),差异无统计学意义(P>0.05)。结论:阿奇霉素肠溶胶囊与红霉素肠溶胶囊对小儿咳嗽变异性哮喘合并MP感染均有一定效果,且安全性相近,但阿奇霉素肠溶胶囊在抑制炎症方面更具优势。

环酯红霉素干混悬剂、胶囊与片剂的生物等效性研究

目的:评价环酯红霉素干混悬剂、胶囊与片剂的生物等效性。方法:18名健康志愿者采用开放、随机、三周期交叉的单中心试验。采用HPLC-MS法测定口服给药后不同时间环酯红霉素的血药浓度。利用DAS 2．0计算药动学参数和进行统计分析。结果:受试者口服750 mg参比制剂环酯红霉素片,受试制剂环酯红霉素干混悬剂和胶囊的C_(max)分别为(1375±s 261)Ixg·L^(-1),(1303土356)μg·L^(-1)和(1307±305)μg·L^(-1);t_(max)分别是(2．4±0．8)h,(2．4±1．0)h和(2．9±0．9)h;4UC_(0～48)分别是(13302±4 369)μg·h·L^(-1),(13596±5519)μg·h·L^(-1)和(13564±4 825)μg·h·L^(-1)。受试制剂的相对生物利用度分别为(102±17)％,(102±15)％。结论:环酯红霉素干混悬剂和胶囊与剂量相同的环酯红霉素片参比制剂具有生物等效性。

红霉素联合雷贝拉唑治疗反流性食管炎的疗效观察

目的观察红霉素肠溶胶囊联合雷贝拉唑治疗反流性食管炎的临床效果。方法将符合诊断标准的反流性食管炎患者100例,随机分为治疗组52例,采用红霉素肠溶胶囊联合雷贝拉唑治疗;对照组48例只用雷贝拉唑治疗。观察两组治疗前及治疗4周后的临床疗效以及内镜下病症改善的程度。结果治疗4周后治疗组有效率为94.2%;对照组有效率为79.1%,两组比较有显著性差异(P<0.05)。内镜下反流性食管炎症状改善程度治疗组显著好于对照组(P<0.05)。两组均未见严重不良反应。结论红霉素联合雷贝拉唑是治疗反流性食管炎安全、有效的方法。

姜黄消痤擦剂治疗轻中度痤疮31例疗效观察

目的:探讨姜黄消痤擦剂联合红霉素肠溶胶囊与阿达帕林凝胶联合红霉素肠溶胶囊治疗轻中度痤疮的临床疗效。方法:根据随机单盲对照的试验原则将62例病人分为A组和B组,各31例,A组病人给予姜黄消痤擦剂联合红霉素肠溶胶囊,早晚各1次;B组病人给予阿达帕林凝胶联合红霉素肠溶胶囊,早晚各1次,8周后观察2组病人的皮损状况。结果:2组治疗总有效率分别为74.2%和77.4%,差异无统计学意义(P>0.05)。A组未出现不良反应,B组面部瘙痒伴脱皮7例,差异有统计学意义(P<0.05)。结论:姜黄消痤擦剂联合红霉素肠溶胶囊疗效显著,且不良反应少,值得临床广泛应用。

异维A酸红霉素凝胶在寻常性中重度痤疮治疗中的应用

目的探讨异维A酸红霉素凝胶应用于寻常性中、重度痤疮治疗的效果。方法选择2010年9月～2011年9月就诊的73例寻常性中、重度痤疮患者,分为观察组和对照组,对照组采用维胺脂维E乳膏外用治疗,观察组采用异维A酸红霉素凝胶外用治疗,治疗2个月后比较两组患者的临床疗效及不良反应情况,并对临床效果进行综合评价。结果观察组总有效率为83.78%,对照组总有效率为63.89%,两组总有效率比较差异有统计学意义(P<0.05);观察组6例出现不良反应,对照组8例出现不良反应。两组不良反应率比较差异无统计学意义(P>0.05)。结论异维A酸红霉素凝胶外用治疗寻常性中、重度痤疮,疗效较好,值得临床进一步推广。

紫外分光光度法测定红霉素肠溶胶囊中红霉素的含量

目的:建立红霉素肠溶胶囊的含量测定方法。方法:采用紫外分光光度法,红霉素与氢氧化钠溶液反应生成在235nm波长处有最大吸收峰的不饱和酮,根据不饱和酮的紫外吸收值来确定红霉素肠溶胶囊的含量。结果:红霉素在51.18~307.08μg·ml^(-1)的浓度范围内线性关系良好(r=0.999 9),平均回收率为99.9%,RSD为1.2%(n=6)。结论:该方法简便、准确、灵敏度高、重复性好,可用于红霉素肠溶胶囊的含量测定。

自拟疏肝清肺饮治疗成年女性轻中度痤疮的临床观察

目的 探讨自拟方疏肝清肺饮治疗成年女性轻、中度痤疮的临床效果.方法 选取首都医科大学良乡教学医院皮肤科门诊年龄25～ 45岁的女性轻、中度痤疮患者86例,按患者单双日就诊次序随机分为2组单日就诊为对照组,双日就诊为观察组.对照组40例口服红霉素肠溶胶囊0.5g/次,2次/d;同时外用0.025％的维A酸乳膏,1次/晚.观察组46例口服自拟疏肝清肺饮,每日1剂,分2次服用;同时也外用0.025％的维A酸乳膏,1次/晚.疗程6周,每周随访1次.疗程结束后分别比较2组患者的治疗效果.结果 对照组患者有效率为75.0％ （30/40）;观察组患者有效率为87.0％ （40/46）,2组的有效率比较差异无统计学意义（P＞0.05）.结论 自拟方疏肝清肺饮配合外用维A酸乳膏治疗成年女性轻、中度痤疮与红霉素肠溶胶囊加维A酸乳膏具有相近的疗效,为临床治疗这类痤疮患者提供了新的选择.

分光光度法测定红霉素肠溶胶囊溶出度的研究

本文建立了红霉素胶囊剂的溶出度检查法。采用转蓝法，以盐酸（9→1000）为酸性溶液，转速50r／min，溶出1h，再以pH6．8磷酸盐缓冲液为溶剂，经溶出1h，取溶出液的续滤液5ml，加入硫酸溶液（75→100）5ml，混匀，放置30min，用分光光度法测定，测定波长为482nm，测定浓度为55μg／ml，同时用对照品对照。依法测定红霉素胶囊6批，溶出量均不少于85％。

红霉素肠溶胶囊治疗呼吸道感染80例

目的 :观察红霉素肠溶胶囊治疗呼吸道感染的临床疗效、安全性。方法 :80例轻中度呼吸道感染患者用红霉素肠溶胶囊 5 0 0mg ,bid ,疗程 5～ 7d。观察治疗前后临床症状与体征 ,记录可能与使用该药相关的各种不良反应。结果 :痊愈 45例 ,显效 2 6例 ,进步 7例 ,无效 2例 ,痊愈率与总有效率分别为 5 6 .3%和 88.8%。共分离出 16株细菌 ,其中11株细菌敏感 ,4株中介度 ,1株耐药。细菌清除率 93.7%。轻度恶心、上腹部不适 4例 ,大便次数增加 2例 ,未经特殊处理 ,症状消失。另 2例恶心、呕吐 ,1例出现严重腹泻 ( 7次·d 1 ) ,不能耐受治疗而停药。不良反应总发生率 10 .8%。 48例治疗前后肝、肾功能均未见异常 ,5 3例治疗前后血、尿常规检查正常。结论 :红霉素肠溶胶囊治疗呼吸道感染有效率和细菌清除率高 ,疗效显著 ,安全。

循证药学在促进临床合理应用抗生素中的作用

目的:探讨循证药学在促进临床合理应用抗生素中的作用。方法:2011年6月-2012年8月收治呼吸道感染患者70例,随机分为观察组和对照组,依据循证药学的方法,对照组采用红霉素肠溶胶囊进行治疗,观察组采用青霉素钠进行治疗,对比两组患者的临床疗效和病症的改善情况。结果:治疗1个疗程以后,观察组的临床疗效显著优于对照组,差异具有统计学意义(P<0.05)。观察组炎症吸收、啰音消失、咳喘恢复、血象恢复、退热等病症的改善效果显著优于对照组,同时观察组的治疗时间短于对照组,差异具有统计学意义(P<0.05)。结论:对患者依据循证药学的方法使用青霉素钠进行治疗,疗效显著,治疗时间短,治疗预后效果好,具有临床价值意义,可以大力推广。

一清胶囊配合异维A酸红霉素凝胶治疗寻常痤疮临床观察

目的观察一清胶囊配合异维A酸红霉素凝胶治疗寻常痤疮的临床疗效。方法 80例寻常痤疮患者随机分为治疗组和对照组各40例,均外用异维A酸红霉素凝胶,1次·d-1,疗程均为8周,治疗组同时加用一清胶囊。结果 8周后治疗组和对照组总有效率分别为77.50%和55.00%,疗效差异有统计学意义(P=0.033)。结论一清胶囊配合异维A酸红霉素凝胶治疗寻常痤疮临床疗效确切,优于单用异维A酸红霉素凝胶治疗。

润燥止痒胶囊、异维A红霉素凝胶联合治疗痤疮108例临床研究

目的对润燥止痒胶囊联合异维A红霉素凝胶治疗痤疮的效果进行分析探讨。方法将我院108例寻常痤疮患者随机分为对照组和观察组,对照组采用异维A红霉素凝胶治疗,观察组采用润燥止痒胶囊联合异维A红霉素凝胶治疗,对比两组患者的治疗有效率及不良反应的发生率。结果观察组的治疗有效率高于对照组(P<0.05),观察组的不良反应的发生率低于对照组(P<0.05)。结论润燥止痒胶囊联合异维A红霉素凝胶治疗痤疮能够提高治疗效果,降低不良反应的发生率。

复方珍珠暗疮胶囊联合维胺脂胶囊及异维A酸红霉素凝胶治疗寻常痤疮68例临床观察

目的观察复方珍珠暗疮胶囊联合维胺脂胶囊及异维A酸红霉素凝胶治疗寻常痤疮的临床疗效。方法将入选的135例寻常痤疮患者随机分成两组,治疗组68例,口服复方珍珠暗疮胶囊1.2g,维胺脂胶囊50mg,均3次/d,同时外用异维A酸红霉素凝胶早、晚各1次;对照组67例,仅予口服维胺脂胶囊和外用异维A酸红霉素凝胶,用法同治疗组。两组患者的疗程均为4周。结果治疗组有效率94.12%,对照组有效率58.21%,差异有统计学意义(P<0.05)。两组外用异维A酸红霉素凝胶后诉面部有不同程度的干燥、脱皮、刺痛,末见胃肠道不良事件。结论复方珍珠暗疮胶囊联合维胺脂胶囊及异维A酸红霉素凝胶治疗寻常痤疮有效率高,值得临床选用。

Effect of Weikang Capsule(胃康胶囊)on Aspirin-Related Gastric and Small Intestinal Mucosal Injury

Objective To investigate the effects of Weikang Capsule(胃康胶囊,WKC)on aspirin-related gastric and small intestinal mucosal injury by magnetically controlled capsule endoscopy(MCCE).Methods Patients taking enteric-coated aspirin aged 40-75 years were enrolled in Beijing Anzhen Hospital,Capital Medical University from January 2019 to December 2019.The patients continued taking aspirin Tablet(100 mg per day)and underwent MCCE before and after 1-month combined treatment with WKC(0.9 g per time orally,3 times per day).The gastrointestinal symptom score,gastric Lanza score,the duodenal,jejunal and ileal mucosal injury scores were used to evaluate the gastrointestinal injury before and after treatment.Adverse events including nausea,vomiting,abdominal pain,abdominal distension,abdominal discomfort,dizziness,or headache during MCCE and combined treatment were observed and recorded.Results Twenty-two patients(male/female,13/9)taking enteric-coated aspirin aged 59.5±11.3 years with a duration of aspirin use of 28.0(1.0,48.0)months were recruited.Compared with pre-treatment,the gastrointestinal symptom rating scale scores,gastric Lanza scores,and duodenal mucosal injury scores were significantly reduced after 1-month WKC treatment(P<0.05),and jejunal and ileal mucosal injury scores showed no obvious change.No adverse events occurred during the trial.Conclusions WKC can alleviate gastrointestinal symptoms,as well as gastric and duodenal mucosal injuries,in patients taking enteric-coated aspirin;it does not aggravate jejunal or ileal mucosal injury,which may be an effective alternative for these patients(Clinical trial registry No.ChiCTR1900025451).

双歧杆菌三联活菌联合多潘立酮治疗新生儿喂养不耐受40例

目的观察双歧杆菌三联活菌联合多潘立酮对新生儿喂养不耐受的疗效和用药安全性。方法选取2012年1月至2014年1月喂养不耐受新生儿124例随机分成3组,对照组A40例给予红霉素治疗,对照组B40例给予多潘立酮治疗,治疗组44例给予双歧杆菌三联活菌联合多潘立酮治疗,均以7 d为1个疗程,对比3组患儿呕吐、腹胀及胃潴留的消失时间,达到胃肠足量喂养的时间,1周内日体质量增长状况。结果治疗组呕吐和胃潴留症状消失时间、治疗5 d达全胃肠喂养例数、治疗1周体重增长值与对照组比较,差异有统计学意义(P<0.05),治疗组优于对照组。结论双歧杆菌三联活菌联合多潘立酮治疗新生儿喂养不耐受,疗效理想,方法较为简便,适合临床推广。

高效液相色谱法测定红霉素肠溶胶囊的含量

目的建立测定红霉素肠溶胶囊含量的高效液相色谱法。方法色谱柱为Diamonsil C18柱(250 mm×4.6 mm,5μm),流动相为0.067 mol/L磷酸二氢铵溶液(用三乙胺调pH至6.5)-乙腈(58∶42),检测波长为210 nm,流速为1.0 mL/min,柱温为30℃。结果质量浓度线性范围为20～140 g/L(r=0.999 9),平均加样回收率为100.14%,RSD为0.29%(n=6)。结论所用方法简便、准确、灵敏度高、重现性好,可用于红霉素肠溶胶囊的含量测定。